Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants

The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike protein as an immunogen. As expected of RNA v...

Descripción completa

Detalles Bibliográficos
Autores principales: Carnell, George W., Billmeier, Martina, Vishwanath, Sneha, Suau Sans, Maria, Wein, Hannah, George, Charlotte L., Neckermann, Patrick, Del Rosario, Joanne Marie M., Sampson, Alexander T., Einhauser, Sebastian, Aguinam, Ernest T., Ferrari, Matteo, Tonks, Paul, Nadesalingam, Angalee, Schütz, Anja, Huang, Chloe Qingzhou, Wells, David A., Paloniemi, Minna, Jordan, Ingo, Cantoni, Diego, Peterhoff, David, Asbach, Benedikt, Sandig, Volker, Temperton, Nigel, Kinsley, Rebecca, Wagner, Ralf, Heeney, Jonathan L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995963/
https://www.ncbi.nlm.nih.gov/pubmed/36911730
http://dx.doi.org/10.3389/fimmu.2023.1118523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995963/
https://www.ncbi.nlm.nih.gov/pubmed/36911730
http://dx.doi.org/10.3389/fimmu.2023.1118523

Ejemplares similares